Literature DB >> 28383367

Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.

Alexander Melamed1, Roni Nitecki, David M Boruta, Marcela G Del Carmen, Rachel M Clark, Whitfield B Growdon, Annekathryn Goodman, John O Schorge, J Alejandro Rauh-Hain.   

Abstract

OBJECTIVE: To compare 3-year survival, length of hospitalization, perioperative mortality, risk of readmission, and residual disease associated with laparoscopic and laparotomic interval debulking surgery among women with epithelial ovarian cancer.
METHODS: We used the National Cancer Database to identify a cohort of patients diagnosed with stage IIIC and IV epithelial ovarian cancer between 2010 and 2012 who underwent neoadjuvant chemotherapy and interval debulking surgery. We compared 3-year overall survival, duration of postoperative hospitalization, 90-day postoperative mortality, and residual disease status between women who underwent interval debulking by laparoscopy and by laparotomy. We used the Kaplan-Meier method and Cox regression models in survival analyses. At a significance of .05, this study had 80% power to detect an 8% difference in 3-year survival. The main analysis was intention to treat.
RESULTS: We identified 3,071 women meeting inclusion criteria, of whom 450 (15%) underwent surgery initiated laparoscopically. There was no difference in 3-year survival between patients undergoing laparoscopy [47.5%; 95% confidence interval (CI) 41.4-53.5] and laparotomy (52.6%; 95% CI 50.3-55.0; P=.12). Survival did not differ after adjustment for demographic characteristics, facility type, presence of comorbidities, and stage (adjusted hazard ratio, 1.09; 95% CI 0.93-1.28; P=.26). Postoperative hospitalization was slightly shorter in the laparoscopy group (median 4 compared with 5 days, P<.001). Frequency of readmission (5.3% compared with 3.7%; P=.26), death within 90 days of surgery (2.8% compared with 2.9%, P=.93), and suboptimal debulking (20.6% compared with 22.6%, P=.29) did not differ between patients undergoing laparoscopy and laparotomy.
CONCLUSION: Ovarian cancer patients selected for laparoscopic interval debulking surgery after neoadjuvant chemotherapy have 3-year survival rates similar to women who undergo interval debulking by laparotomy. Laparoscopy is associated with a modestly shorter postoperative hospitalization, whereas readmission rates and risk of perioperative death are similar for the surgeries.

Entities:  

Mesh:

Year:  2017        PMID: 28383367     DOI: 10.1097/AOG.0000000000001851

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

1.  Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer.

Authors:  Sarah A Ackroyd; Sajeena Thomas; Cynthia Angel; Richard Moore; Philip J Meacham; Brent DuBeshter
Journal:  J Robot Surg       Date:  2017-06-19

2.  Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.

Authors:  Christianne Persenaire; Adam Pyrzak; Emma L Barber
Journal:  J Minim Invasive Gynecol       Date:  2021-10-11       Impact factor: 4.137

3.  Laparoscopic and Laparotomic Restaging in Patients With Apparent Stage I Epithelial Ovarian Cancer: A Comparison of Surgical and Oncological Outcomes.

Authors:  Yongxue Wang; Jie Yin; Yan Li; Ying Shan; Yu Gu; Ying Jin
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

4.  Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).

Authors:  Roni Nitecki; Jose Alejandro Rauh-Hain; Alexander Melamed; Giovanni Scambia; Rene Pareja; Robert L Coleman; Pedro T Ramirez; Anna Fagotti
Journal:  Int J Gynecol Cancer       Date:  2020-07-20       Impact factor: 3.437

5.  Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.

Authors:  Joel Cardenas-Goicoechea; Yu Wang; Susan McGorray; Mohammed D Saleem; Semiramis L Carbajal Mamani; Ariel F Pomputius; Merry-Jennifer Markham; Jacqueline C Castagno
Journal:  J Robot Surg       Date:  2018-07-10

6.  Perioperative and Survival Outcomes of Robotic-Assisted Surgery, Comparison with Laparoscopy and Laparotomy, for Ovarian Cancer: A Network Meta-Analysis.

Authors:  Qin Tang; Weichu Liu; Dan Jiang; Junying Tang; Qin Zhou; Jing Zhang
Journal:  J Oncol       Date:  2022-04-30       Impact factor: 4.501

7.  The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis.

Authors:  Anne Knisely; Charlotte R Gamble; Caryn M St Clair; June Y Hou; Fady Khoury-Collado; Allison A Gockley; Jason D Wright; Alexander Melamed
Journal:  J Minim Invasive Gynecol       Date:  2020-11-14       Impact factor: 4.314

8.  [Care management and elective carcinological surgery place during the COVID-19 pandemic: A case report].

Authors:  M Vermel; L Lecointre; É Faller; T Boisramé; C Akladios
Journal:  Gynecol Obstet Fertil Senol       Date:  2020-05-14

9.  Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study.

Authors:  Semiramis L Carbajal-Mamani; David Schweer; Merry J Markham; Ashwini K Esnakula; Joseph R Grajo; Jacqueline C Castagno; Joel Cardenas-Goicoechea
Journal:  Obstet Gynecol Sci       Date:  2020-02-10

10.  Robot-assisted laparoscopic debulking surgery for recurrent adult granulosa cell tumors.

Authors:  Jolijn W Groeneweg; Joline F Roze; Wouter B Veldhuis; Jelle P Ruurda; Cornelis G Gerestein; Ronald P Zweemer
Journal:  Gynecol Oncol Rep       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.